Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
JAK1 / JAK2 protein kinase inhibitor Baricitinib, 5 mg  

JAK1 / JAK2 protein kinase inhibitor Baricitinib, 5 mg

2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(ethylsulfonyl)azetidin-3-yl)acetonitrile

Synonyms: LY3009104, INCB028050
Baricitinib is a selective and orally bioavailable JAK1/JAK2 inhibitor.

More details

PKI-BARIC-005

Availability: within 3 days

136,50 €

Background: Baricitinib is a selective and orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM). LY3009104 is ~70 and ~10-fold selective versus JAK3 and Tyk2 and displays no inhibition to c-Met and Chk2. INCB028050 inhibits intracellular signaling of multiple proinflammatory cytokines including IL-6 and IL-23 at concentrations <50 nM.

Chemical formula: C16H17N7O2S
Molecular weight: 371.42 g/mol
Purity: 99 %
Appearance: White solid
Solubility: Soluble in 0.1N HCl (aq) and DMSO
CAS Number: 1187594-09-7

Manufacturer:  Axon Medchem BV

PLEASE NOTE: This product is designed for research purposes and can only be delivered to academic and business customers.  

References

JS Fridman et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J. Immunol. 2010, 184(9), 5298-5307.